BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IBSAL - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IBSAL
X-ORIGINAL-URL:https://ibsal.es/en/
X-WR-CALDESC:Events for IBSAL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261021
DTEND;VALUE=DATE:20270130
DTSTAMP:20261026T092118Z
CREATED:20261026T090010Z
LAST-MODIFIED:20261026T092118Z
UID:29119-1792540800-1801267199@ibsal.es
SUMMARY:International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award
DESCRIPTION:Features\nFunding from the International Myeloma Society (IMS) and the Paula and Rodger Riney Foundation supports translational research projects on multiple myeloma and other plasma cell disorders. Their goal is to advance findings that can be translated into clinical practice\, thereby improving the prevention\, early detection\, diagnosis\, and treatment of these diseases.  It is essential that the project have a clear translational focus and a result that is potentially applicable in clinical practice; basic research on myeloma alone is not sufficient. \nTranslational research projects are accepted in all areas of plasma cell disorders\, particularly multiple myeloma. The research areas considered include:  \n\n\n\n\nDevelopment of biomarkers and methods for diagnosis or early detection. \n\n\n\n\n\n\nNew molecular and imaging techniques. \n\n\n\n\n\n\nDevelopment and evaluation of drugs or biological agents. \n\n\n\n\n\n\nIdentification of new therapeutic targets using human biological samples\, including those from clinical trials. \n\n\n\n\n\n\nPreclinical or clinical research with the potential to change the way myeloma is prevented\, diagnosed\, or treated. \n\n\n\n\nThe project must have an initial duration of 12 months\, although an extension for an additional year may be requested on an exceptional basis. Funding covers personnel expenses\, laboratory supplies\, services\, and travel. Inventory items are not permitted unless their necessity is specifically justified.   Funding ranging from 175\,000 USD to 250\,000 USD per project. \nRequirements:\n\n\n\n\nPrincipal Investigator (PI) Profile: The PI must be a university professor (faculty member) or an established researcher with an MD and/or PhD. \n\n\n\n\n\n\nResearch experience: We are seeking a researcher with a proven track record. Researchers from other fields who wish to focus their research on myeloma are also encouraged to apply.  \n\n\n\n\n\n\nIMS Membership: The principal investigator or one of the co-investigators must be a member of the International Myeloma Society. \n\n\n\n\n\n\nAcknowledgment Requirement: Publications and presentations resulting from this grant must acknowledge the IMS and the Paula and Rodger Riney Foundation as sources of funding. \n\n\n\n\n\n\nTranslational impact: The proposal must explain how its results can be translated into clinical practice. \n\n\n\n\nWomen and researchers from underrepresented groups are especially encouraged to submit applications \nHow to apply\nThe application must be completed in English. The following documentation is required:  \n\nOfficial application form. It must be completed and approved by the institution. \nScientific report\, bibliographic references\, scientific CV (biosketch)\, budget\, and statement of eligibility and translation.\n\nApplications are submitted through the IMS Grant Management System \nThe call for applications for 2027 is now open\, and the deadline is January 29\, 2027\, at 11:59 p.m. (EST) (the deadline corresponds to 5:59 a.m. on January 30\, 2027\, Spanish peninsular time).
URL:https://ibsal.es/en/evento/international-myeloma-society-ims-and-paula-and-rodger-riney-foundation-translational-research-award/
CATEGORIES:Calls for research
END:VEVENT
END:VCALENDAR